| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 |
| Sales | 3,844,430 | 3,438,680 | 2,921,590 | 2,752,700 | 2,613,840 |
| Sales Growth | +11.80% | +17.70% | +6.14% | +5.31% | +10.38% |
| Net Income | 292,150 | 191,120 | 339,020 | 362,480 | 96,360 |
| Net Income Growth | +52.86% | -43.63% | -6.47% | +276.17% | +1.34% |
Stada Arzneimi Namen (STDAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Stada Arzneimittel AG manufactures pharmaceuticals for pain, women's health, cardiovascular conditions and diabetes. The company's branded product consists of Grippostad (R) and Ladival(R). Stada Arzneimittel AG is headquartered in Bad Vilbel, Germany.
Fiscal Year End Date: 12/31